Ventas, Inc. (NYSE:VTR – Get Free Report) Director Walter Rakowich sold 1,152 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $90.20, for a total transaction of $103,910.40. Following the completion of the sale, the director directly owned 28,349 shares of the company’s stock, valued at approximately $2,557,079.80. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ventas Stock Performance
VTR traded down $2.49 on Friday, reaching $87.47. The company had a trading volume of 3,814,691 shares, compared to its average volume of 3,555,031. Ventas, Inc. has a 1 year low of $61.76 and a 1 year high of $91.06. The stock has a market capitalization of $42.53 billion, a PE ratio of 159.04, a P/E/G ratio of 2.22 and a beta of 0.74. The company has a quick ratio of 0.25, a current ratio of 0.25 and a debt-to-equity ratio of 0.95. The stock has a 50-day moving average price of $85.04 and a 200-day moving average price of $81.21.
Ventas (NYSE:VTR – Get Free Report) last announced its quarterly earnings results on Monday, April 27th. The real estate investment trust reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Ventas had a net margin of 4.25% and a return on equity of 2.09%. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same period last year, the firm earned $0.84 earnings per share. Ventas’s revenue was up 22.0% on a year-over-year basis. Ventas has set its FY 2026 guidance at 3.820-3.890 EPS. As a group, research analysts forecast that Ventas, Inc. will post 3.85 EPS for the current fiscal year.
Ventas Announces Dividend
Analyst Ratings Changes
VTR has been the subject of a number of research reports. Mizuho upped their target price on shares of Ventas from $87.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Argus set a $88.00 target price on shares of Ventas in a report on Tuesday, February 10th. Royal Bank Of Canada upped their target price on shares of Ventas from $91.00 to $98.00 and gave the company an “outperform” rating in a report on Monday, May 4th. KeyCorp upped their target price on shares of Ventas from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company upped their target price on shares of Ventas from $88.00 to $93.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Ventas has an average rating of “Moderate Buy” and a consensus price target of $94.00.
Institutional Investors Weigh In On Ventas
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Dynamic Wealth Strategies LLC purchased a new position in Ventas during the first quarter worth about $25,000. GoalVest Advisory LLC purchased a new position in Ventas during the fourth quarter worth about $26,000. Cloud Capital Management LLC purchased a new position in Ventas during the third quarter worth about $25,000. Wiser Advisor Group LLC purchased a new position in Ventas during the third quarter worth about $27,000. Finally, IFC & Insurance Marketing Inc. purchased a new position in Ventas during the fourth quarter worth about $30,000. 94.18% of the stock is owned by hedge funds and other institutional investors.
Ventas Company Profile
Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas’ business model combines property ownership with active asset management and capital markets activity.
See Also
- Five stocks we like better than Ventas
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.
